Safety and efficacy of astegolimab for COPD with frequent exacerbations regardless of baseline blood eosinophil counts (ALIENTO and ARNASA): randomised, double-blind, placebo-controlled, phase 2b and 3 trials. (linkinghub.elsevier.com)

Authors: Papi A … Brightling CE Journal: The Lancet Published: 2026-05-23 DOI: https://doi.org/10.1016/S0140-6736(26)00637-9